Cargando…

ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses

Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encod...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Magnus A. G., Yang, Zhi, Huey-Tubman, Kathryn E., Cohen, Alexander A., Gnanapragasam, Priyanthi N. P., Nakatomi, Leesa M., Storm, Kaya N., Moon, Woohyun J., Lin, Paulo J.C., Bjorkman, Pamela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810232/
https://www.ncbi.nlm.nih.gov/pubmed/36597535
http://dx.doi.org/10.1101/2022.12.26.521940
_version_ 1784863268654809088
author Hoffmann, Magnus A. G.
Yang, Zhi
Huey-Tubman, Kathryn E.
Cohen, Alexander A.
Gnanapragasam, Priyanthi N. P.
Nakatomi, Leesa M.
Storm, Kaya N.
Moon, Woohyun J.
Lin, Paulo J.C.
Bjorkman, Pamela J.
author_facet Hoffmann, Magnus A. G.
Yang, Zhi
Huey-Tubman, Kathryn E.
Cohen, Alexander A.
Gnanapragasam, Priyanthi N. P.
Nakatomi, Leesa M.
Storm, Kaya N.
Moon, Woohyun J.
Lin, Paulo J.C.
Bjorkman, Pamela J.
author_sort Hoffmann, Magnus A. G.
collection PubMed
description Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses.
format Online
Article
Text
id pubmed-9810232
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-98102322023-01-04 ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses Hoffmann, Magnus A. G. Yang, Zhi Huey-Tubman, Kathryn E. Cohen, Alexander A. Gnanapragasam, Priyanthi N. P. Nakatomi, Leesa M. Storm, Kaya N. Moon, Woohyun J. Lin, Paulo J.C. Bjorkman, Pamela J. bioRxiv Article Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses. Cold Spring Harbor Laboratory 2022-12-27 /pmc/articles/PMC9810232/ /pubmed/36597535 http://dx.doi.org/10.1101/2022.12.26.521940 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Hoffmann, Magnus A. G.
Yang, Zhi
Huey-Tubman, Kathryn E.
Cohen, Alexander A.
Gnanapragasam, Priyanthi N. P.
Nakatomi, Leesa M.
Storm, Kaya N.
Moon, Woohyun J.
Lin, Paulo J.C.
Bjorkman, Pamela J.
ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title_full ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title_fullStr ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title_full_unstemmed ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title_short ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses
title_sort escrt recruitment to mrna-encoded sars-cov-2 spike induces virus-like particles and enhanced antibody responses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810232/
https://www.ncbi.nlm.nih.gov/pubmed/36597535
http://dx.doi.org/10.1101/2022.12.26.521940
work_keys_str_mv AT hoffmannmagnusag escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT yangzhi escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT hueytubmankathryne escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT cohenalexandera escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT gnanapragasampriyanthinp escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT nakatomileesam escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT stormkayan escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT moonwoohyunj escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT linpaulojc escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses
AT bjorkmanpamelaj escrtrecruitmenttomrnaencodedsarscov2spikeinducesviruslikeparticlesandenhancedantibodyresponses